Evidence map›Paper›PMID 22056502›Full record

SynthesisCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2012

Fine-mapping CASP8 risk variants in breast cancer.

Nicola J Camp, Marina Parry, Stacey Knight, Ryan Abo, Graeme Elliott, Sushilaben H Rigas, Sabapathy P Balasubramanian, Malcolm W R Reed, Helen McBurney, Ayse Latif and 4 more

Open access · greenAbstract readMeta-Analysis
In one paragraph

Synthesis in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Journal of Cancer · 2018
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Hereditary breast cancer: ever more pieces to the polygenic puzzle.Hereditary cancer in clinical practice · 2013
    Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Nicola J CampDivision of Genetic Epidemiology, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Marina Parry
Stacey Knight
Ryan Abo
Graeme Elliott
Sushilaben H Rigas
Sabapathy P Balasubramanian
Malcolm W R Reed
Helen McBurney
Ayse Latif
William G Newman
Lisa A Cannon-Albright
D Gareth Evans
Angela Cox
Mayo Clinic · USUniversity of Manchester · GBWinnMed · USUniversity of Utah · USGeorge E. Wahlen Department of VA Medical Center · USUniversity of Sheffield · GB

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
GENETIC EPIDEMIOLOGY OF CHRONIC LYMPHOCYTIC LEUKEMIAR01CA134674 · NCI · UNIVERSITY OF UTAH · PI CAMP, NICOLA J. · 2010 to 2016
$3.8M
Breast Cancer Now 2004NOV49Cancer Research UK A11292Cancer Research UK C9528/A11292NCI NIH HHS HHSN261201000026CNCI NIH HHS P30 CA042014NCI NIH HHS P30 CA42014NCI NIH HHS R01 CA134674Yorkshire Cancer Research S295Yorkshire Cancer Research S299
6 · The paper itself

Abstract

backgroundMultiple genome-wide and candidate gene association studies have been conducted in search of common risk variants for breast cancer. Recent large meta analyses, consolidating evidence from these studies, have been consistent in highlighting the caspase-8 (CASP8) gene as important in this regard. To define a risk haplotype and map the CASP8 gene region with respect to underlying susceptibility variant/s, we screened four genes in the CASP8 region on 2q33-q34 for breast cancer risk.

methodsTwo independent data sets from the United Kingdom and the United States, including 3,888 breast cancer cases and controls, were genotyped for 45 tagging single nucleotide polymorphisms (tSNP) in the expanded CASP8 region. SNP and haplotype association tests were carried out using Monte Carlo-based methods.

resultsWe identified a three-SNP haplotype across rs3834129, rs6723097, and rs3817578 that was significantly associated with breast cancer (P < 5 × 10(-6)), with a dominant risk ratio and 95% CI of 1.28 (1.21-1.35) and frequency of 0.29 in controls. Evidence for this risk haplotype was extremely consistent across the two study sites and also consistent with previous data.

conclusionThis three-SNP risk haplotype represents the best characterization so far of the chromosome upon which the susceptibility variant resides. IMPACT: Characterization of the risk haplotype provides a strong foundation for resequencing efforts to identify the underlying risk variant, which may prove useful for individual-level risk prediction, and provide novel insights into breast carcinogenesis.

Indexed as

AdultAgedAged, 80 and overBreast NeoplasmsCase-Control StudiesCaspase 8FemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyHaplotypesHumansMiddle AgedPolymorphism, Single NucleotideCaspase 8

Identifiers

PMID22056502
PMCPMC3253962
OpenAlexW2106430859

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.